ĒVOLVERE BIOSCIENCES LTD


Directors	Piotr Karol Jedryszek
	Weronika Anna Slesak
	Oliver James Waterhouse
	Adam John Winnifrith


Registered Address	167-169 Great Portland Street
	London
	W1W 5PF


Registered Number	13396961 (England and Wales)

Balance Sheet as at
31 December 2025

	Notes	2025		2024
		£	£	£	£
Current assets
Debtors	3	21,393		12,085
Cash at bank and on hand		2,236		11,150
		23,629		23,235
Creditors amounts falling due within one year	4	(193,328)		(47,995)
Net current assets (liabilities)			(169,699)		(24,760)
Total assets less current liabilities			(169,699)		(24,760)
Net assets			(169,699)		(24,760)
Capital and reserves
Share premium			100,001		100,001
Profit and loss account			(269,700)		(124,761)
Shareholders' funds			(169,699)		(24,760)

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 25 September 2026, and are signed on its behalf by:

Adam John Winnifrith
Director
Registered Company No. 13396961

ĒVOLVERE BIOSCIENCES LTD

Notes to the Financial Statements
for the year ended 31 December 2025

1.	Accounting policies

	Statutory information
	The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

	Statement of compliance
	The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

	Going concern
	After the financial year end the company ceased trading, and the directors have therefore prepared these financial statements on a basis other than going concern (the break up basis).

	Turnover policy
	Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services.

	Employee benefits
	Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.

Employee benefits

Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.

2.	Average number of employees


		2025		2024
	Average number of employees during the year	6		1

3.	Debtors: amounts due within one year

	2025	2024
	£	£
Other debtors	19,621	10,485
Prepayments and accrued income	1,772	1,600
Total	21,393	12,085

4.	Creditors: amounts due within one year

	2025	2024
	£	£
Trade creditors / trade payables	-	4,451
Amounts owed to related parties	174,074	33,545
Other creditors	19,254	9,999
Total	193,328	47,995

5.	Contingent liabilities
	There were no financial guarantees or commitments, either ongoing or entered into during the period.

6.	Directors advances, credits and guarantees
	There were no advances, credits and guarantees granted to the directors during the period

7.	Off-balance sheet arrangements
	The company had no off-balance sheet arrangements at year-end or at any stage during the period.

8.	Related party transactions
	As at 31 December 2025, the company owed £174,073.92 to its parent, Ēvolvere Biosciences Inc.

9.	Controlling party
	The company’s immediate and ultimate parent undertaking, and controlling party, is Ēvolvere Biosciences Inc., incorporated in United States.